Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

Summary

Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC). Zr-89-girentuximab PET/CT (Positron Emission Tomography) may be a valuable imaging technique in the diagnosis of patients with RCC. The aim of the present study is to show the impact of the Zr-89-girentuximab PET/CT on the clinical management of ccRCC patients.

Timeline

Start

2015-12

Primary completion

2017-06-06

Completion

2017-06-06

Drugs

Indications